olivLaw · US equity research
Elevance Health, Inc. ELV
Hospital & Medical Service Plans · SIC 6324 · Vertical: Hospital & Medical Service Plans (SIC 6324)
Elevance Health is one of the largest health insurers in the United States, with approximately 44.9 million medical members as of September 30, 2026. In the third quarter of 2026 operating revenue was 50.4 billion USD, up 0.7%, and management raised FY 2026 diluted EPS guidance to at least 22.00 USD. The Carelon segment could support growth, but the company remains exposed to medical costs and government program rules.
At the close of 04 Nov 2026, Elevance Health, Inc. (ELV) stock was 434.18 USD (+4.94% on the day), with market capitalisation 93.8 bn USD, P/E 18.5 on diluted EPS of 23.45 USD over the last 12 months, dividend yield 1.58%, beta 0.23, 52-week range 280.74–445.28 USD. Latest reported quarter (Q3 2026): revenue of 51.4 bn USD (+1.4% YoY), net income of 1.4 bn USD (+14.8% YoY), diluted EPS 6.27 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 58.9
- strong (55–70)
- Bollinger (20, 2)
- 403.95 – 446.69
- in the upper half of the band · %B 0.71 · band width 10.0%
- SMA 50 / 200
- 411.75 / 373.04
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 3.69 / 5.21
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +10.1% | −1.1% | +11.2 pp | — |
| 3 months | +11.0% | −0.5% | +11.4 pp | — |
| 6 months | +15.9% | +4.4% | +11.5 pp | — |
| Year to date | +23.9% | +12.3% | +11.5 pp | — |
| 1 year | +37.1% | +13.5% | +23.6 pp | +52.7% |
| 3 years | −3.5% | +76.4% | −79.9 pp | +8.5% |
| 5 years | +2.9% | +63.7% | −60.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45.4 bn | 48.9 bn | 49.8 bn | 50.7 bn | 49.7 bn | 50.2 bn | 50.5 bn | 51.4 bn |
| Cost of revenue | 6.0 bn | 5.0 bn | 5.3 bn | 5.4 bn | 5.5 bn | 5.5 bn | 5.5 bn | 5.6 bn |
| SG&A | 4.8 bn | 5.3 bn | 5.0 bn | 5.3 bn | 5.4 bn | 6.3 bn | 5.5 bn | 5.8 bn |
| Operating income | 673.0 m | 3.2 bn | 2.4 bn | 1.3 bn | 309.0 m | 2.1 bn | 1.8 bn | 1.3 bn |
| Depreciation & amortisation | 706.0 m | 373.0 m | 380.0 m ≈ | 387.0 m ≈ | 406.0 m | 354.0 m | 366.0 m ≈ | 363.0 m ≈ |
| Interest expense | 340.0 m | 344.0 m | 341.0 m | 351.0 m | 366.0 m | 357.0 m | 364.0 m | 358.0 m |
| Pre-tax income | 606.0 m | 2.8 bn | 2.3 bn | 1.4 bn | 215.0 m | 2.3 bn | 1.9 bn | 1.8 bn |
| Income tax | 193.0 m | 613.0 m | 548.0 m | 219.0 m | -331.0 m | 544.0 m | 483.0 m | 451.0 m |
| Net income | 418.0 m | 2.2 bn | 1.7 bn | 1.2 bn | 547.0 m | 1.8 bn | 1.5 bn | 1.4 bn |
| Diluted EPS | 1.81 ≈ | 9.61 | 7.72 | 5.32 | 2.47 ≈ | 8.00 | 6.71 | 6.27 |
| Operating cash flow | 706.0 m | 1.0 bn | 2.1 bn ≈ | 1.1 bn ≈ | 84.0 m | 4.3 bn | 1.9 bn ≈ | 1.3 bn ≈ |
| Capex | 322.0 m | 196.0 m | 267.0 m ≈ | 360.0 m ≈ | 293.0 m | 235.0 m | 287.0 m ≈ | 267.0 m ≈ |
| Dividends paid | 373.0 m | 386.0 m | 385.0 m | 381.0 m | 377.0 m | 376.0 m | 373.0 m | 373.0 m |
| Share repurchases | 1.8 bn | 880.0 m | 378.0 m ≈ | 876.0 m ≈ | 471.0 m | 1.1 bn | 234.0 m ≈ | 330.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 75 percentile of its own 44-quarter history (min 11.4, median 16.8, max 22.4; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 92.1 bn | 104.2 bn | 121.9 bn | 138.6 bn | 156.6 bn | 171.3 bn | 177.0 bn | 199.1 bn |
| Revenue YoY | +2.3% | +13.1% | +16.9% | +13.8% | +13.0% | +9.4% | +3.3% | +12.5% |
| Net income | 3.8 bn | 4.8 bn | 4.6 bn | 6.2 bn | 5.9 bn | 6.0 bn | 6.0 bn | 5.7 bn |
| Net income YoY | −2.4% | +28.2% | −4.9% | +34.7% | −4.3% | +1.6% | −0.1% | −5.3% |
| Diluted EPS | 14.19 | 18.47 | 17.98 | 24.95 | 24.28 | 25.22 | 25.68 | 25.21 |
| Diluted EPS YoY | −1.1% | +30.2% | −2.7% | +38.8% | −2.7% | +3.9% | +1.8% | −1.8% |
| net % | 4.1% | 4.6% | 3.8% | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| Free cash flow | 2.6 bn | 5.0 bn | 9.7 bn | 7.3 bn | 7.2 bn | 6.8 bn | 4.6 bn | 3.2 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 9.5 bn USD
- Financial debt
- 30.9 bn USD
- Net debt
- 21.5 bn USD
- Equity
- 44.0 bn USD
- Total assets
- 121.5 bn USD
- Debt / equity
- 0.70x
- Current ratio
- 1.54x
- ROE
- 13.3%
- ROA
- 4.8%
- FCF margin
- 1.6%
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Pre-tax income | 6.2 bn | 8.0 bn | 7.6 bn | 7.7 bn | 7.9 bn | 6.7 bn | SEC (XBRL)· 06 Feb 2026verified |
| Net income | 4.6 bn | 6.2 bn | 5.9 bn | 6.0 bn | 6.0 bn | 5.7 bn | SEC (XBRL)· 06 Feb 2026verified |
| Diluted EPS | 17.98 | 24.95 | 24.28 | 25.22 | 25.68 | 25.21 | SEC (XBRL)· 06 Feb 2026verified |
| Dividend per share | 3.80 | 4.52 | 5.12 | 5.92 | — | — | SEC (XBRL)· 21 Feb 2024verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 5.7 bn | 4.9 bn | 7.4 bn | 6.5 bn | 8.3 bn | 9.5 bn | SEC (XBRL)· 06 Feb 2026verified |
| Total assets | 86.6 bn | 97.5 bn | 102.8 bn | 108.9 bn | 116.9 bn | 121.5 bn | SEC (XBRL)· 06 Feb 2026verified |
| Short-term debt | 0 | 275.0 m | 265.0 m | 225.0 m | 365.0 m | 150.0 m | SEC (XBRL)· 06 Feb 2026verified |
| Long-term debt | 19.3 bn | 21.2 bn | 22.3 bn | 23.2 bn | 29.2 bn | 30.8 bn | SEC (XBRL)· 06 Feb 2026verified |
| Total liabilities | 53.4 bn | 61.3 bn | 66.4 bn | 69.5 bn | 75.5 bn | 77.5 bn | SEC (XBRL)· 06 Feb 2026verified |
| Equity | 33.2 bn | 36.1 bn | 36.3 bn | 39.4 bn | 41.4 bn | 44.0 bn | SEC (XBRL)· 06 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Dividends paid | 954.0 m | 1.1 bn | 1.2 bn | 1.4 bn | 1.5 bn | 1.5 bn | SEC (XBRL)· 06 Feb 2026verified |
| Share repurchases | 2.7 bn | 1.9 bn | 2.3 bn | 2.7 bn | 2.9 bn | 2.6 bn | SEC (XBRL)· 06 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Market and valuation
Insurance
32 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 61 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 93.8 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation79
- Returns44
- Quality50
- Balance sheet100
- Growth44
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 77.79 – 1,358.04 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- Residual income212.76 – 222.48 (Mid 217.53)
- Justified P/B241.16 – 324.32 (Mid 276.63)
- Dividend discount (DDM)77.79 – 104.62 (Mid 89.24)
- Peers: P/E569.98 – 1,358.04 (Mid 610.34)7 companies used · median multiple 26.0x · quartiles 24.3x – 57.9xALHC, CI, CNC, HUM, OSCR, TRUP, UNH
- Peers: P/B433.14 – 693.44 (Mid 573.04)6 companies used · median multiple 2.8x · quartiles 2.1x – 3.4xCI, CNC, HUM, MOH, TRUP, UNH
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 61/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROE · Quality | 11.6% | 50 (vs peers) | 20% |
| Loss ratio · Quality | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | 1.3% | 13 (on a fixed band) | 11% |
| Revenue CAGR 3Y · Growth | 8.3% | 83 (on a fixed band) | 9% |
| ROA · Balance sheet | 4.1% | 100 (on a fixed band) | 9% |
| P/B · Valuation | 2.1x | 71 (vs peers) | 16% |
| P/E (TTM) · Valuation | 18.5x | 86 (vs peers) | 16% |
| Dividend yield · Returns | 1.6% | 10 (on a fixed band) | 11% |
| Payout ratio (EPS) · Returns | 29.3% | 100 (on a fixed band) | 7% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 1/1 factors with a value
- Growth44/100 · 2/2 factors with a value
- Quality· partial50/100 · 1/2 factors with a value
- Returns44/100 · 2/2 factors with a value
- Valuation79/100 · 2/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Elevance Health, Inc. (ELV). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: YoY growth 12.5%; net margin 2.5%; ROE 11.6%.
The estimated value range is 241.16–324.32 USD per share (median of 5 methods, agreement: low); assumptions are illustrative. Against the central value of 276.63 USD, the price of 434.18 USD leaves a potential of -36.3% (value / price − 1) and a margin of safety of -57.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 61/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: quality. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 8.3%
- ROA: 4.1%
- P/B: 2.1x
- P/E (TTM): 18.5x
- Payout ratio (EPS): 29.3%
What contradicts it
- EPS CAGR 3Y: 1.3%
- Dividend yield: 1.6%
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Loss ratio.
Versus the vertical median
Hospital & Medical Service Plans (SIC 6324) · same industry (4-digit SIC) · compared with 9 companies
The size band was not applied: too few companies would have remained; the vertical includes much smaller or larger companies.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| UNHUnitedHealth Group Incorporated | 366.8 bn | 23.4 | 15.4% | 3.5% | +11.8% | +24% / −26% |
| ELVElevance Health, Inc. | 93.8 bn | 18.5 | 11.6% | 2.5% | +12.5% | +37% / −3% |
| CIThe Cigna Group | 80.7 bn | 13.2 | 15.0% | 2.2% | +11.2% | +10% / +16% |
| HUMHumana Inc | 50.1 bn | 44.5 | 6.2% | 0.8% | +10.1% | +70% / −14% |
| CNCCentene Corporation | 37.6 bn | 26.0 | 6.8% | 0.7% | +19.4% | +93% / +3% |
| MOHMolina Healthcare, Inc. | 11.8 bn | — | -1.2% | -0.1% | +11.7% | +53% / −38% |
| ALHCAlignment Healthcare, Inc. | 1.7 bn | 71.3 | 13.2% | 0.6% | +46.1% | −58% / +9% |
| TRUPTrupanion, Inc. | 1.5 bn | 74.8 | — | — | +11.9% | −5% / +31% |
| OSCROscar Health, Inc. | — | 25.2 | 34.3% | 3.6% | +27.5% | +96% / +314% |
| CLOVClover Health Investments, Corp. | — | — | -5.1% | -0.7% | +40.3% | +88% / +409% |
1- and 3-year price returns: for ELV from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 270.38 Total return -36% · Per year -36% | 477.15 Total return 12% · Per year 12% | 717.56 Total return 67% · Per year 67% |
| 3 years | 283.04 Total return -31% · Per year -12% | 560.05 Total return 35% · Per year 10% | 921.75 Total return 119% · Per year 30% |
| 5 years | 296.30 Total return -25% · Per year -6% | 657.34 Total return 62% · Per year 10% | 1,184.05 Total return 186% · Per year 23% |
- Exit P/E± 140.01
- Net margin± 98.01
- Annual revenue growth± 77.60
- Annual dilution± 8.24
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Elevance Health is one of the largest health insurers in the United States, with approximately 44.9 million medical members as of September 30, 2026 2. In the third quarter of 2026 operating revenue was 50.4 billion USD, up 0.7% 3, and management raised FY 2026 diluted EPS guidance to at least 22.00 USD 3. The Carelon segment could support growth, but the company remains exposed to medical costs and government program rules 1.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Cost forecastinghigh
Errors in benefit cost estimates can hurt profitability, and Medicare and Medicaid rates are set months ahead 1.
- Geographic concentrationmedium
Significant revenue comes from a few states, exposing the company to regional economic downturns 1.
- Data securityhigh
Cyber-attacks and privacy breaches could bring remediation costs and litigation 1.
- Public Exchange rulesmedium
Changes to subsidies and compliance requirements could affect market stability 12.
- Reliance on the CVS agreementlow
New CVS terms and termination rights could change how CarelonRx delivers pharmacy services 2.
Investment thesis
What would need to be true (bull case)
- If the operating trends of the third quarter of 2026 continue, the raised 2026 guidance could be supported by operating results 3.
- The Carelon segment, with its risk-based services, could become a growth engine beyond traditional insurance 3.
- National scale and the BCBS licence could keep advantages in large employer contracts 1.
What to watch
- Quarterly results and 2026 guidanceQ4 2026
- Benefit expense ratio trendQ1 2027
- Adjusted EPS growth target for 20272027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Elevance Health operates risk-based health plans, administrative services for self-funded customers and pharmacy and health services through its Carelon brand, under a licence from the Blue Cross and Blue Shield Association 1. As of December 31, 2025 the company served approximately 45.2 million medical members 1. It reports four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other 1.
Revenue comes from risk-based premiums, administrative fees from self-funded employers and pharmacy and health service fees 1. In fiscal 2025 about 32% of consolidated revenue came from U.S. government agencies, mainly within Health Benefits 1. Strategy centres on integrating medical, pharmacy and behavioural care around a whole-health model 1.
Segments
Health Benefits
Health Benefits offers risk-based medical plans for individual, employer, Medicare, Medicaid and FEP members, plus administrative services for fee-based customers 1. In the third quarter of 2026 segment revenue was 43.4 billion USD, with operating gain lower than a year earlier because of targeted investments 3.
Corporate & Other
Corporate & Other holds businesses below segment thresholds and unallocated corporate costs, including investment in technology and long-term initiatives 1.
Market context
The company is among the largest U.S. insurers by medical membership 1. Membership eased from 45.2 million at December 31, 2025 to 44.9 million at September 30, 2026, with declines in Medicaid and Medicare Advantage 12.
Product pricing remains competitive, and Medicare and Medicaid rates may lag underlying cost trends 2. Participation in Public Exchange markets stays sensitive to subsidies and regulation, which could affect enrolment 12.
Trends
- High medical cost trendsheadwind
Service utilisation, high-cost drugs and labour pressures have kept cost trends elevated, especially in Medicaid 2.
- Medicaid redetermination and morbidityheadwind
Members moving from Medicaid into the individual ACA market and lower effectuation rates have raised morbidity, which could keep pressuring costs if the pattern persists 2.
- Growth in Carelon servicestailwind
Risk-based Carelon services and better specialty pharmacy profitability supported segment operating gain 3.
- New five-year CVS agreementmixed
CarelonRx signed a new five-year agreement with CVS starting January 1, 2027, which could provide continuity but introduces new operating terms 2.
Competitive position
The company competes with other large insurers for employer, Medicare, Medicaid and Public Exchange business, where price plays a major role in plan choice 1. The BCBS licence and BlueCard network help in large multistate contracts, but price competition remains intense 12.
In pharmacy and health services, CarelonRx and Carelon Services compete with specialist pharmacy benefit managers and managed care service providers 12.
- Large national health insurers (commercial and Medicare plans)
Nationwide insurers are the main rivals for employer contracts and Medicare plans 1.
- Pharmacy services and benefit management providers
In pharmacy, CarelonRx competes with specialist providers offering comparable drug management services 2.
- Other Blue Cross and Blue Shield licensees
BCBS licensees compete locally but cooperate through BlueCard on multistate contracts 1.
- Medicaid and Medicare Advantage service providers
In Medicaid and Medicare Advantage, competition runs on rates, quality results and CMS Star Ratings 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Turkish pop icon releases climate anthem for COP31Hürriyet Daily News — Türkiye (TR, EN) · 03 Nov 2026 · EN
- Tws returns with uplifting anthem for youth's trial and errorYonhap News (KR, EN) · 01 Nov 2026 · EN
- Öngyilkos lett Lauren Bennett, a Party Rock Anthem énekesnőjeIndex.hu English (HU) · 30 Oct 2026 · EN
- What is the history behind Trump’s LeBron blast over US national anthem?Al Jazeera English · 22 Oct 2026 · EN
- Trump says NBA star LeBron James disrespected US national anthemAl Jazeera English · 22 Oct 2026 · EN
- Trump says LeBron James showed disrespect during US national anthemCNA (Channel NewsAsia) · 22 Oct 2026 · EN
- Elevance Raises Full-Year Guidance on Lower Medical CostsBloomberg Markets · 21 Oct 2026 · EN
- Trump’s envoy calls return of Russian flag, anthem to Paralympians meaningful stepTASS (RU, EN) · 15 Oct 2026 · EN
- With flag, anthem, ambition: Russian judokas to compete at World Championships in BakuTASS (RU, EN) · 03 Oct 2026 · EN
- I-dle's Soyeon sweeps charts with anthem about quitting workYonhap News (KR, EN) · 21 Sept 2026 · EN
- Asian Games offer 'deepest apologies' for South Korea anthem blunderCNA (Channel NewsAsia) · 19 Sept 2026 · EN
- (Asiad) Organizing committee apologizes for playing N. Korean anthem at S. Korean hockey matchYonhap News (KR, EN) · 19 Sept 2026 · EN
- North Korean anthem played for South Korea at Asian GamesBBC World News · 18 Sept 2026 · EN
- North Korea anthem played at South’s Bangladesh hockey match at Asian GamesAl Jazeera — World · 18 Sept 2026 · EN
- Bungling Asian Games chiefs play North Korean anthem for South KoreaCNA (Channel NewsAsia) · 18 Sept 2026 · EN
- Iranian football players who sought asylum in Australia say anthem silence was protest against TehranThe Hindu — International · 07 Sept 2026 · EN
- How Is Elevance Health’s Stock Performance Compared to Other Health Providers?Yahoo Finance — News · 02 Sept 2026 · EN
- Elevance Health (ELV) Soars as Investors Gain Confidence in ProfitabilityYahoo Finance — News · 01 Sept 2026 · EN
- Elevance Health (ELV): Bridging the Gap between Care and CoverageYahoo Finance — News · 01 Sept 2026 · EN
- Is Elevance Health (ELV) a Mispriced Opportunity?Yahoo Finance — News · 25 Aug 2026 · EN
SEC filings
- Quarterly report21 Oct 2026
- Current report21 Oct 2026Results of operations · Financial statements and exhibits
- Current report10 Sept 2026Regulation FD disclosure
- Quarterly report15 Jul 2026
- Current report15 Jul 2026Results of operations · Financial statements and exhibits
- Current report10 Jun 2026Regulation FD disclosure
- Current report13 May 2026Shareholder vote
- Quarterly report22 Apr 2026
- Current report22 Apr 2026Results of operations · Financial statements and exhibits
- Proxy statement27 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Elevance Health, Inc. · 06 Feb 2026
- [2] Form 10-Q, quarter ended 2026-09-30 · SEC / Elevance Health, Inc. · 21 Oct 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Elevance Health, Inc. · 21 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.